https://www.selleckchem.com/pr....oducts/blebbistatin.
For the literal scenario, 32% were eligible in EF50% (38% of EF40%, 20% of EF 40-49%) and 22% in EF≥40% (25% for EF≥50%). Eligible vs. noneligible patients had more severe HF, more comorbidities and overall worse outcomes. In a real-world HF outpatient cohort, 81% of patients had EF50%, with 63% eligible for sacubitril/valsartan based on pragmatic criteria and 32% eligible based on literal trial criteria. Similar eligibility was observed for EF 40-49% and ≥50%, suggesting that our estimates for EF50% may be reproduc
Like
Comment
Share
